JO3464B1 - التركيبات الخاصة بمركبات التياكوميسين - Google Patents

التركيبات الخاصة بمركبات التياكوميسين

Info

Publication number
JO3464B1
JO3464B1 JOP/2014/0006A JOP20140006A JO3464B1 JO 3464 B1 JO3464 B1 JO 3464B1 JO P20140006 A JOP20140006 A JO P20140006A JO 3464 B1 JO3464 B1 JO 3464B1
Authority
JO
Jordan
Prior art keywords
compositions
polymorph
carrageenan
solvate
isomer
Prior art date
Application number
JOP/2014/0006A
Other languages
English (en)
Inventor
Hikaru Saito
Yoshiyuki Murakami
Original Assignee
Astellas Pharma Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47563169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3464(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Europe Ltd filed Critical Astellas Pharma Europe Ltd
Application granted granted Critical
Publication of JO3464B1 publication Critical patent/JO3464B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<span dir="RTL">يوفر الاختراع الحالي تركيبة تشتمل على مركب تباكوميسين واحد أو أكثر كمكون فعال، و متجاسم منه، أو صورة متبلرة منه أو ذوابة منه، في توليفة مع سواغ، مختار من المجموعة التي تتكون من صمغ زانتان، كاراجينان، ألجينات صوديوم، صمغ الجوار، سليلوز قابل للتشتيت في الماء (سيليلوز دقيق التبلر و صوديوم كربوكسي ميثيل سليلوز) و خلائط من ذلك. و أيضا، يوفر الاختراع استخدام سواغ، مختار من المجموعة التي تتكون من صمغ زانتان، كاراجينان، ألجينات صوديوم، صمغ الجوار، سيليلوز قابل للتشتيت في الماء (سيليلوز دقيق التبلر و صوديوم كربوكسي ميثيل سليلوز) و خلائط من ذلك كعامل مضاد للرغوة في تركيبة تشتمل كمكون فعال على مركب تياكوميسين، متجاسم منه، صورة متبلرة منه أو ذوابة منه.</span>
JOP/2014/0006A 2013-01-15 2014-01-13 التركيبات الخاصة بمركبات التياكوميسين JO3464B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13075002 2013-01-15

Publications (1)

Publication Number Publication Date
JO3464B1 true JO3464B1 (ar) 2020-07-05

Family

ID=47563169

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0006A JO3464B1 (ar) 2013-01-15 2014-01-13 التركيبات الخاصة بمركبات التياكوميسين

Country Status (28)

Country Link
US (1) US9808530B2 (ar)
EP (1) EP2945613B1 (ar)
JP (1) JP6338598B2 (ar)
KR (1) KR102181474B1 (ar)
CN (1) CN105120840B (ar)
AR (1) AR094495A1 (ar)
AU (1) AU2014207083B2 (ar)
CA (1) CA2904808A1 (ar)
CY (1) CY1121459T1 (ar)
DK (1) DK2945613T3 (ar)
EA (1) EA030049B1 (ar)
ES (1) ES2705238T3 (ar)
GE (1) GEP201706769B (ar)
HR (1) HRP20182110T1 (ar)
HU (1) HUE041421T2 (ar)
IL (1) IL239899A0 (ar)
JO (1) JO3464B1 (ar)
LT (1) LT2945613T (ar)
MD (1) MD4588C1 (ar)
NZ (1) NZ710875A (ar)
PL (1) PL2945613T3 (ar)
PT (1) PT2945613T (ar)
RS (1) RS58119B1 (ar)
SI (1) SI2945613T1 (ar)
TW (1) TWI646962B (ar)
UA (1) UA117004C2 (ar)
WO (1) WO2014111254A1 (ar)
ZA (1) ZA201505048B (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015169451A1 (en) 2014-05-09 2015-11-12 Astellas Pharma Europe Ltd Treatment regimen tiacumicin compound
CN110037992B (zh) * 2019-05-28 2021-05-28 杭州华东医药集团新药研究院有限公司 一种稳定的非达霉素组合物
CN116715678B (zh) * 2023-06-12 2025-09-30 中国科学院成都生物研究所 一种吲哚糖碳苷类大环化合物及其制备方法与应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3000792A (en) 1957-05-21 1961-09-19 Merck & Co Inc Antibiotic adsorption process
GB1458512A (en) 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4632902A (en) 1981-08-20 1986-12-30 Becton, Dickinson And Company Method for detecting biological activity in a body fluid
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
CA2384519C (en) 1991-03-04 2006-08-15 Bayer Corporation Automated analyzer
US5583115A (en) 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US5767096A (en) 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
ES2312695T3 (es) 1996-11-18 2009-03-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilones e y f.
JP2000072760A (ja) 1998-06-19 2000-03-07 Ajinomoto Co Inc 新規シストチアゾール類縁体
JP2000053514A (ja) 1998-08-06 2000-02-22 Aquas Corp レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法
JP2000239266A (ja) 1999-02-17 2000-09-05 Ajinomoto Co Inc 新規ポリエン系抗生物質
AU2001295195B2 (en) 2000-04-28 2007-02-01 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US20070105791A1 (en) 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US7507564B2 (en) 2002-07-29 2009-03-24 Optimer Pharmaceuticals, Inc. Tiacumicin production
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
AU2003301121A1 (en) 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
WO2005009474A1 (ja) 2003-07-24 2005-02-03 Shionogi & Co., Ltd. 難水溶性薬物を含むドライシロップ剤
JP3881640B2 (ja) 2003-08-08 2007-02-14 塩野義製薬株式会社 ロラタジンを含むドライシロップ剤
ES2713954T3 (es) 2004-05-14 2019-05-24 Merck Sharp & Dohme Tratamiento de enfermedades asociadas al uso de antibióticos
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
KR101203118B1 (ko) 2005-01-31 2012-11-20 옵티머 파마슈티칼즈, 인코포레이티드 18-원자 거대고리들 및 그 유사체들
US20110104267A1 (en) * 2005-04-25 2011-05-05 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
CN102503994A (zh) 2005-10-21 2012-06-20 奥普蒂姆药物公司 治疗艰难梭菌相关的腹泻的方法
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
ZA200905337B (en) 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
US8999395B2 (en) * 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
JP5608880B2 (ja) * 2010-02-09 2014-10-22 林兼産業株式会社 嚥下困難者用高栄養ゼリー食品
CN102030791B (zh) 2010-10-28 2013-01-23 中国科学院南海海洋研究所 四种台勾霉素类化合物及其制备方法和在制备抗菌药物中的应用
CN102115757B (zh) 2010-12-14 2015-10-28 中国科学院南海海洋研究所 台勾霉素的生物合成基因簇及其应用

Also Published As

Publication number Publication date
MD20150070A2 (ro) 2016-01-31
WO2014111254A1 (en) 2014-07-24
DK2945613T3 (en) 2019-01-14
CN105120840A (zh) 2015-12-02
HUE041421T2 (hu) 2019-05-28
EP2945613A1 (en) 2015-11-25
CA2904808A1 (en) 2014-07-24
ZA201505048B (en) 2020-05-27
ES2705238T3 (es) 2019-03-22
PT2945613T (pt) 2019-01-17
IL239899A0 (en) 2015-08-31
US9808530B2 (en) 2017-11-07
TWI646962B (zh) 2019-01-11
AU2014207083B2 (en) 2018-03-29
CN105120840B (zh) 2019-03-22
KR102181474B1 (ko) 2020-11-23
GEP201706769B (en) 2017-11-10
NZ710875A (en) 2019-10-25
EP2945613B1 (en) 2018-10-10
SI2945613T1 (sl) 2019-02-28
CY1121459T1 (el) 2020-05-29
JP6338598B2 (ja) 2018-06-06
AU2014207083A1 (en) 2015-08-27
TW201440775A (zh) 2014-11-01
JP2016505026A (ja) 2016-02-18
HRP20182110T1 (hr) 2019-02-22
UA117004C2 (uk) 2018-06-11
EA030049B1 (ru) 2018-06-29
US20160045603A1 (en) 2016-02-18
MD4588B1 (ro) 2018-08-31
LT2945613T (lt) 2019-01-10
AR094495A1 (es) 2015-08-05
PL2945613T3 (pl) 2019-05-31
KR20150114498A (ko) 2015-10-12
RS58119B1 (sr) 2019-02-28
EA201591226A1 (ru) 2016-01-29
MD4588C1 (ro) 2019-03-31

Similar Documents

Publication Publication Date Title
MX391180B (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo
PL2958913T3 (pl) Agoniści receptora sfingozyno-1-fosforanowego, sposoby ich przygotowania i zawierające je jako środek aktywny farmaceutyczne kompozycje
PH12016500170A1 (en) Formulation of syk inhibitors
JO3773B1 (ar) معدلات p2x7
NZ711982A (en) Cytotoxic and anti-mitotic compounds, and methods of using the same
NZ716840A (en) Combination formulation of two antiviral compounds
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MX2016007547A (es) Composiciones para cuidado oral que comprenden carbonato de calcio y arcilla.
MX341200B (es) Composicion farmaceutica de disolucion rapida.
MX2016007838A (es) Composiciones para el cuidado oral que contienen carbonato de calcio y silice.
UA115357C2 (uk) Похідні піридин-4-ілу
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
GEP20186825B (en) Formulation comprising hypolipidemic agent
JO3464B1 (ar) التركيبات الخاصة بمركبات التياكوميسين
MX2015015537A (es) Formulacion de pastillas de nicotina.
PH12015501643B1 (en) Methods of use of phenoxypropylamine compounds to treat depression
IN2013MU03565A (ar)
IN2013MU03309A (ar)
IN2013MU02442A (ar)
MX2023006909A (es) Metodos de uso de compuestos de fenoxipropilamina para tratar la depresion.
MY178005A (en) High water content oral compositions comprising microcrystalline cellulose and carboxymethylcellulose
TH148843A (th) องค์ประกอบสำหรับใช้ในปากที่มีปริมาณน้ำสูงซึ่งประกอบรวมด้วยไมโครคริสตัลไลน์เซลลูโลส และคาร์บอกซีเมธิลเซลลูโลส